Myasthenia Gravis (Chronic Weakness)

November 6, 2006

Aspreva reported negative preliminary results from a phase III trial of CellCept for the treatment of myasthenia gravis. This randomized, double-blind, placebo-controlled clinical trial enrolled subjects diagnosed with myasthenia gravis who received treatment for 36 weeks. Treatment was generally well tolerated, with the most commonly reported adverse events including diarrhea and muscle spasms. However, the trial failed to meet the primary endpoint of achieving minimal disease activity while maintaining designated low steroid and cholinesterase inhibitor doses. Based on the results, Aspreva plans to further analyze the data to determine a future course of action for the development of CellCept.

Related Medical Areas